摘要
目的:观察恩替卡韦的临床效果及不良反应,评价其疗效以及安全性。方法:应用恩替卡韦治疗30例HBV DNA阳性的慢性乙型肝炎患者,观察周期为96周,根据实验结果,评价其临床疗效和安全性。结果:30例慢性乙型肝炎患者治疗24周、48周、96周时,HBV DNA阴转率分别为73.3%(22/30)、86.7%(26/30)和93.3%(28/30),差异具有统计学意义(P<0.05);治疗期间未发生与恩替卡韦用药相关的不良反应。结论:恩替卡韦治疗慢性乙型肝炎不仅具有显著疗效,而且用药安全。
Objective： To investigate the efficacy and ADR of entecavir and evaluate the security of entecavir.Method： Thirty patients with hepatitis B took ETV for 96 weeks.According to the results,the evaluation on the efficacy of in the treatment of patients and the security were carried out.Result： In the CHB group,the rates of HBV DNA negativity at week of 24,48,96 were 73.3%（22/30）,86.7%（26/30） and 93.3%（28/30）,and it was statistically significant（P0.05）.No serious ADR was observed in the patients during the treatment.Conclusion： Entecavir is a kind of effective and safe drug in treatment of patients with CHB.
出处
《河北医学》
CAS
2012年第10期1421-1423,共3页
Hebei Medicine
